Tumor-associated antigens from ID8 ovarian cancer cell lysate (ID8-TAA)

Tumor-associated antigens from ID8 ovarian cancer cell lysate represent a complex mixture of proteins, lipids, and carbohydrates derived from the ID8 mouse ovarian surface epithelial cell line. The ID8 cell line is a widely used syngeneic model for human epithelial ovarian cancer, as it mimics the slow development of peritoneal metastases and ascites. In therapeutic contexts, the lysate serves as a polyvalent antigen source for cancer vaccines, designed to stimulate the immune system to recognize and attack multiple targets simultaneously, thereby reducing the likelihood of tumor escape through antigen loss. When used in immunotherapy, such as in dendritic cell (DC) vaccines, the lysate is internalized by antigen-presenting cells, processed, and presented on MHC class I and II molecules to activate CD8+ and CD4+ T-cells. This approach targets a broad array of antigens, including both known markers like mesothelin and p53, as well as unidentified neoantigens unique to the ID8 lineage. While effective in preclinical murine models for inducing anti-tumor immunity and prolonging survival, the use of whole-cell lysates carries a theoretical risk of inducing autoimmunity against shared self-antigens found in normal ovarian or epithelial tissues.

Other names

ID8 whole cell lysateID8-derived tumor antigensID8 lysateID8-TAAs

Induction of a polyvalent immune response by presenting a broad spectrum of tumor-specific and tumor-associated antigens to the host immune system, typically via dendritic cell loading or direct vaccination with adjuvants.